Lataa...
The Development of Oral Amphotericin B to Treat Systemic Fungal and Parasitic Infections: Has the Myth Been Finally Realized?
Parenteral amphotericin B has been considered as first-line therapy in the treatment of systemic fungal and parasitic infections, however its use has been associated with a number of limitations including affordability, accessibility, and an array of systemic toxicities. Until very recently, it has...
Tallennettuna:
| Julkaisussa: | Pharmaceutics |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
MDPI
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6470859/ https://ncbi.nlm.nih.gov/pubmed/30813569 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/pharmaceutics11030099 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|